Oral and cutaneous manifestations of Erythema Multiforme related to the use of oxcarbazepine in a patient with epilepsy: A case report
DOI:
https://doi.org/10.33448/rsd-v15i2.50685Keywords:
Oxcarbazepine, Erythema multiforme, Epilepsy, Oral medicine, Adverse drug reactions.Abstract
Oxcarbazepine is an anticonvulsant widely used in the treatment of epilepsy; however, it may be associated with mucocutaneous adverse reactions, such as erythema multiforme. This study aims to report a case of erythema multiforme major with oral and cutaneous manifestations associated with oxcarbazepine use in a young patient with epilepsy and neuropsychomotor impairment. A 25-year-old female patient, under continuous oxcarbazepine therapy for more than ten years, presented recurrent episodes of vesiculobullous and ulcerative lesions in the oral cavity, preceding cutaneous lesions on the palmar surface of the hands. Extensive laboratory investigations revealed no significant abnormalities. Lesion remission was observed after discontinuation of oxcarbazepine, with recurrence following drug reintroduction, establishing a causal relationship. Drug replacement combined with systemic and topical corticosteroid therapy resulted in complete lesion resolution. The diagnosis of erythema multiforme was based on clinical features and disease progression. This case highlights the importance of recognizing oral manifestations as early indicators of adverse drug reactions and emphasizes the role of dental professionals in multidisciplinary patient care.
References
Ayangco, L., & Rogers, R. (2003). Oral manifestations of erythema multiforme. Dermatologic Clinics, 21(1), 195–205. https://doi.org/10.1016/S0733-8635(02)00071-5
Arduino, P. G., & Porter, S. R. (2022). Oral manifestations of dermatologic diseases. Oral Diseases, 28(5), 1123–1134. https://doi.org/10.1111/odi.13974
Brodie, M. J., Kwan, P., & Perucca, E. (2022). Epilepsy in adults. The Lancet, 399(10325), 1087–1100. https://doi.org/10.1016/S0140-6736(21)01745-3
Chen, Z., Liew, D., & Kwan, P. (2023). Adverse effects of antiseizure medications: A systematic review. CNS Drugs, 37(2), 127–146. https://doi.org/10.1007/s40263-022-00950-7
Dragnev, N. C., & Wong, S. L. (2018). Do we CARE about the quality of case reports? A systematic assessment. The Journal of surgical research, 231, 428–433. https://doi.org/10.1016/j.jss.2018.07.027
Fang, S., & Gong, Z. C. (2015). Adverse effects of oxcarbazepine. Zhongguo Dang Dai Er Ke Za Zhi, 17(4), 414–419.
Fisher, R. S., Acevedo, C., Arzimanoglou, A., et al. (2014). Practical clinical definition of epilepsy. Epilepsia, 55(4), 475–482. https://doi.org/10.1111/epi.12550
Ghosh, S., Chatterjee, A., Sen, A., & Das, S. (2024). Risk of recurrence after a first unprovoked seizure with different risk factors: A 10-year prospective cohort study. Seizure, 118, 45–52. https://doi.org/10.1016/j.seizure.2024.09.018
International League Against Epilepsy. (2022). Definition and classification of epilepsy: 2022 update. Epilepsia, 63(8), 1811–1823. https://doi.org/10.1111/epi.17315
Kohli, P., & Kaur, J. (2011). Oral variant of erythema multiforme: Case report and literature review. Indian Journal of Otolaryngology and Head & Neck Surgery, 63(Suppl. 1), S9–S12. https://doi.org/10.1007/s12070-011-0184-4
Lerch, M., Mainetti, E. C., Beretta-Piccoli, B. T., & Harr, T. (2018). Current perspectives on erythema multiforme. Current Opinion in Allergy and Clinical Immunology, 18(4), 333–340. https://doi.org/10.1097/ACI.0000000000000450
Löscher, W., Klein, P., & Schmidt, D. (2023). Choosing the right antiepileptic drug: Evidence-based and patient-oriented treatment. The Lancet Neurology, 22(6), 510–522. https://doi.org/10.1016/S1474-4422(23)00074-1
Martinez, R. S., Richarte, D. M. A., Scabar, L. F., & Silva, R. F. (2010). Addressing current aspects of erythema multiforme and dentistry. Journal of Health Sciences Institute, 28(3), 251–254
Mendez-Flores, S., & Palafox-Romo, R. (2024). Cutaneous adverse drug reactions to antiepileptic drugs. Journal of Neurological Disorders & Stroke, 12(1), 1120–1128
Nissen, T., & Wynn, R. (2014). The clinical case report: a review of its merits and limitations. BMC research notes, 7, 264. https://doi.org/10.1186/1756-0500-7-264
Patsalos, P. N., & Szaflarski, J. P. (2023). Clinical pharmacology of oxcarbazepine and its active metabolite. Epilepsy & Behavior, 141, 109026. https://doi.org/10.1016/j.yebeh.2023.109026
Perucca, E., & Johannessen Landmark, C. (2022). Antiepileptic drugs: Mechanisms of action and pharmacokinetics. Epileptic Disorders, 24(1), 7–26. https://doi.org/10.1684/epd.2022.1427
Preuss, C. V., Randhawa, G., Wy, T. S., & Saadanadi, A. (2020). Oxcarbazepine. In StatPearls [Internet]. StatPearls Publishing.
Puranik-Ghodke, Y., Thorn, C. F., Lamba, J. K., et al. (2013). Valproic acid pathway: Pharmacokinetics and pharmacodynamics. Pharmacogenetics and Genomics, 23(4), 236–241. https://doi.org/10.1097/FPC.0b013e32835ea0b2
Rezapour, M., & Mesgarankarimi, A. (2025). Drug-induced erythema multiforme: A case-based review. Journal of Medical Case Reports, 19, 188. https://doi.org/10.1186/s13256-025-05209-y
Rosenthal D. I. (2006). What makes a case report publishable?. Skeletal radiology, 35(9), 627–628. https://doi.org/10.1007/s00256-006-0188-z
Samim, F., Auluck, A., Zed, C., & Williams, P. M. (2013). Erythema multiforme: A review of epidemiology, pathogenesis, clinical features, and treatment. Dental Clinics of North America, 57(4), 583–596. https://doi.org/10.1016/j.cden.2013.07.001
Santini, A. (2019). Spotlight on How to Structure a Case Report. The Journal of Critical Care Medicine,5(2), 76–79. https://doi.org/10.2478/jccm-2019-0007
Sokumbi, O., & Wetter, D. A. (2023). Clinical features, diagnosis, and treatment of erythema multiforme. Mayo Clinic Proceedings, 98(4), 645–656. https://doi.org/10.1016/j.mayocp.2022.10.020
Trayes, K. P., Love, G., & Studdiford, J. S. (2022). Erythema multiforme: Recognition and management. American Family Physician, 105(5), 525–532
Vukičević Lazarević, V. (2024). Erythema multiforme: Current concepts in pathogenesis and management. Exploratory Immunology, 4, 1003188. https://doi.org/10.37349/ei.2024.1003188
Yan, Q., Liu, X., Lei, H., Liu, R., & Hu, Y. (2023). Clinical features of oxcarbazepine-induced Stevens–Johnson syndrome and toxic epidermal necrolysis. Frontiers in Medicine, 10, 1232969. https://doi.org/10.3389/fmed.2023.1232969
Zhu, M.-M., Li, H.-L., & Shi, L.-H. (2017). The pharmacogenomics of valproic acid. Journal of Human Genetics, 62(11), 1009–1014. https://doi.org/10.1038/jhg.2017.87
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Aline do Nascimento Pires, Priscila Faquini Macedo, Patrick Aparecido da Silva Pereira, Luan Borges Venturi, Matheus Branco Elias Dib, André Pereira Falcão
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
